The Phase III SOLO2 (Study of OLaparib in Ovarian cancer) trial (NCT01874353) of olaparib tablets as maintenance monotherapy in patients with platinum-sensitive HSROC and a BRCA1/2 mutation (BRCAm) revealed significantly improved PFS in the olaparib-treated group compared to the placebo group (HR 0.30, 95% CI 0.22–0.41; p < 0.0001) [4]. The gene discussed is BRCA1; the disease is ovarian carcinoma.